Heart failure & cardiomyopathies
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study
Main finding · Mortality or hospitalizationResult — go to the resultHazard ratio 0.78 95% CI 0.74–0.83Authors' conclusion
In ASCVD and HF patients, adding GLP-1 RA to SGLT2i reduces 1-year mortality and hospitalization, warranting further investigation in diverse settings.
Study context
- Population
- Patients with atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) who initiated GLP-1 RA with SGLT2i or SGLT2i alone, 1 August 2016 to 30 September 2024patients meeting inclusion criteria, of 2,797,317 identified, 5272 per group after propensity score matching
- Participants
- 96,051 patients
- Exposure
- Adding GLP-1 RA to SGLT2i vs SGLT2i alone
- GLP-1RA and SGLT2in = 5,272
- SGLT2i alonen = 5,272reference
- Outcome
- Mortality or hospitalization
- Follow-up
- Within 1 year
Methodological detailspropensity score matching, TriNetX database
- Propensity score matching
- TriNetX database
Main finding
As reported in the abstract
Hazard ratio
0.78
95% CI 0.74–0.83
GLP-1RA and SGLT2i vs SGLT2i alone
HR 0.78 (95% CI 0.74–0.83)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| Mortality (secondary) | 0.72 (0.62–0.84) | |
| Hospitalization (secondary) | 0.78 (0.73–0.83) | |
| HFE (secondary) | 0.77 (0.72–0.83) | |
| 0.512Hazard ratio (log scale) |
Subgroup analyses
- Consistent benefits in HFpEF, HFrEF, diabetes, obesity, chronic kidney disease, semaglutide or dulaglutide
- Liraglutide use showed a neutral effect
Original publication
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study. Eur Heart J Cardiovasc Pharmacother. Published 17 February 2025. doi:10.
Summarised from the published abstract; every number is checked against it